Coordination compounds have a long history of use as chemotherapeutic medicines and have advantages over organic compounds. The bioinorganic mechanism and standard pharmacokinetic parameters of uptake, distribution, and excretion are used to assess the potential of coordination compounds as effective anticancer agents (as...
drugs or modifiers of biological response) [1]. Furthermore, medicinal chemists can investigate the potential of metal-containing compounds using a variety of strategies, such as coordination compounds with different coordination numbers, geometries, oxidation states, and ligand substitution thermokinetics [2, 3]. Cisplatin (cis-diamminedichloroplatinum(II)), a platinum-based bifunctional reagent, is an extremely effective chemotherapeutic drug used to treat a variety of malignancies. However, despite their excellent efficacy, these drugs are only used in limited circumstances due to their toxicity, side effects, and acquired resistance in patients [4]. Therefore, to improve therapeutic effectiveness and avoid drawbacks, there is a need for novel platinum and non-platinum-based compounds with potential chemotherapeutic properties [5].

Copper, nickel, and zinc are bio-essential elements and are required for performing various biological functions in the human body. In the field of non-platinum compounds with anticancer properties, complexes with copper, nickel, and zinc have provided a promising alternative to platinum in the development of anticancer drugs, exhibiting activity on cisplatin inactive tumours and the potential to be successful against platinum-resistant malignancies in patients. In addition, copper is also essential for the activity of cytochrome oxidase, superoxide dismutase, ascorbate oxidase, and tyrosinase, enzymes, and proteins involved in energy metabolism, respiration, and DNA synthesis [6]. Furthermore, these metal complexes are likely to have different modes of action, bio-distribution, and toxicity than platinum-based medicines. In addition, the design of ligands associated with metal ions has a considerable impact on drug transport to the target position [7, 8]. Schiff bases, also known as “privileged ligands,” have a characteristic imine linkage and are frequently used as pharmophores for drug design because of their easy synthesis and high solubility in organic solvents. Furthermore, Schiff bases exhibit significant biological activity owing to the interaction of azomethine nitrogen with protein amino acid residues or DNA nucleobases [9–11].

Over the past several years, dithiocarbazate Schiff bases have gained considerable interest because of their promising bioactivities against various cancer cells [12–15]. However, the biological applications of these compounds become changed by the addition of different organic substituents, resulting in even minor structural modifications [12, 16–18]. Furthermore, dithiocarbazate Schiff bases coordinate with the metal ions to form a wide range of metal complexes with numerous biological applications [12, 13, 15–18]. Therefore, considering the diverse significance of dithiocarbazate Schiff bases and their role in a variety of biological applications, herein we are interested to design a novel dithiocarbazate Schiff base ligand (Figure 1) and its complexes with Cu(II), Ni(II), and Zn(II) ions. The ligand and its complexes are characterized by various spectroscopic methods and single-crystal X-ray crystallography in the case of ligand and complex 2. All the synthesized compounds have been tested to evaluate anticancer activity against MCF-7 and MDA-MB-213 cancer cell lines. Single-crystal X-ray diffraction and Hirshfeld surface studies were used to better define the geometric structure of 1 and 3. The experimental data were investigated using density functional theory (DFT), and the shape of complex 2 was optimized for molecular docking simulations using DFT.

2. Experiments

2.1. Materials and Instrumentation. All chemicals and solvents were used without any purification. Chemicals used are as follows: 2-methoxybenzaldehyde (Merck), copper(II) acetate (Univar), nickel(II) acetate tetrahydrate (Fluka), zinc(II) acetate dihydrate (Fluka), and nitric acid (65%) (Fisher). Solvents used are as follows: acetonitrile (Baker), ethanol (99.8%, Scharlau), methanol (Fisher), and dimethyl sulfoxide (Scharlau).

An electrothermal digital melting point equipment was used to measure the melting points, whereas the magnetic susceptibilities were determined at 25°C using a Sherwood Scientific MSB-AUTO magnetic susceptibility balance. A JENWAY 4310 conductivity meter was used to determine the molar conductivities of the complexes in DMSO at 10−3 M at 27°C. PerkinElmer Spectrum 100 with universal ATR polarization was used to measure FTIR spectra at 4000–280 cm−1. A LECO CHNS-932 analyzer was used to perform analyses of C, H, and N. A Perkin–Elmer Plasma 1000 Emission Spectrometer was used to do metal measurements. Shimadzu UV-1650PC UV-Visible Spectrophotometer was used to measure the electronic spectra at 1000–200 nm. An NMR JNM ECA400 spectrometer was used to record the 1H and 13C NMR spectra of 1, while those of 3 and 4 were determined by a Bruker Ascend™ 700 MHz spectrometer. A Shimadzu GC-MS QP2010 plus mass spectrometer was used to collect the mass spectra.

2.2. Synthesis of S-4-Methylbenzyl-β-N-(2-Methoxybenzylmethylene)dithiocarbazate Ligand (1). The dithiocarbazate derivative, S-(4-methylbenzyl)dithiocarbazate (S4MBDTC), was synthesized using a reported procedure [12, 18, 19]. S4MBDTC (2.12 g, 0.01 mol) was dissolved (100 mL) in the mixture of hot ethanol and acetonitrile (Scheme 1). An equimolar amount of 2-methoxybenzaldehyde was added to the hot dithiocarbazate solution and refluxed at 70°C for 5 h and then stirred for another 5 h until a precipitate is formed at room temperature, which was then filtered and dried over silica gel, yielding yellow crystals on recrystallization in acetonitrile.

Yield: 81%. Melting point: 167–169°C. Anal. Cal.: C, 61.79; H, 5.49; and N, 8.48%. Found: C, 62.11; H, 5.40; and N, 9.09%. FTIR (ATR, cm−1): 3105 ν(N–H), 1600 ν(C=N), 1153

---

**Figure 1: Structure of ligand 1.**
2.3. General Method for Synthesizing Complexes, \([M \left( \text{L}\right)_{2}]\) \([M = \text{Cu(II)}, \text{Ni(II)}, \text{Zn(II)}\) (2), \(\text{Ni(II)}\) (3), and \(\text{Zn(II)}\) (4)]. The hot acetonitrile solution of ligand, 1 (0.66 g, 0.002 mol), was combined with an alcoholic solution of \(\text{M (CH}_3\text{COO)}_2\), \(\text{H}_2\text{O}\) \([\text{M} = \text{Cu(II)}, \text{Ni(II)}, \text{Zn(II)}\) in 1:1 molar ratio (Scheme 1). The reaction mixture was stirred and refluxed at 70°C for 3 hours, which was subsequently allowed to cool at room temperature, resulting in the formation of a precipitate. The precipitate was separated and purified by drying it over silica gel, followed by recrystallization in methanol. We were successful in obtaining single crystals for 3. However, despite our best efforts, we failed to grow single crystals suitable for single-crystal X-ray diffraction for 2 and 4.

Copper(II) Complex (2). Green powder. Yield: 80%. M.p.: 180–182°C. Anal. Cal.: C, 56.52; H, 4.74; N, 7.75; and Cu, 8.80%. Found: C, 56.59; H, 4.45; N, 8.01; and Cu, 8.53%. FTIR (ATR, cm\(^{-1}\)) : 1596 \(\nu (C = N)\), 1100 \(\nu (N = N)\), and 944 \(\nu (C = S)\). \(^1\text{H NMR (CDCl}_3\) \(\delta (ppm): 2.35 (CH}_3\), 3.78 (s, 6H, O-CH\(_3\)), 3.88 (s, 4H, CH\(_2\)), 7.04–7.75 (m, 16H, aromatic-H), and 8.40 (s, 2H, CH). \(^{13}\text{C NMR (DMSO-d}_6\) \(\delta (ppm): 21.2 (CH}_3\), 39.6 (CH\(_2\)), 55.4 (O-CH\(_3\)), 112.4, 117.2, 117.6, 119.1, 121.8, 126.0, 128.9, 129.3, 129.4, 132.8, 133.1, 135.3 (Ar-C), 159.4, 159.8 (C = N), and 168.4 (C-S-C).

Nickel(II) Complex (3). Brown crystals. Yield: 83%. M.p.: 182–183°C. Anal. Cal.: C, 56.91; H, 4.78; N, 7.81; and Ni, 8.18%. Found: C, 56.47; H, 4.72; N, 8.57; and Ni, 8.39%. FTIR (ATR, cm\(^{-1}\)) : 1589 \(\nu (C = N)\), 1107 \(\nu (N = N)\), and 964 \(\nu (C = S)\). \(^1\text{H NMR (CDCl}_3\) \(\delta (ppm): 2.35 (CH}_3\), 3.78 (s, 6H, O-CH\(_3\)), 3.88 (s, 4H, CH\(_2\)), 7.04–7.75 (m, 16H, aromatic-H), and 8.40 (s, 2H, CH). \(^{13}\text{C NMR (DMSO-d}_6\) \(\delta (ppm): 21.2 (CH}_3\), 39.6 (CH\(_2\)), 55.4 (O-CH\(_3\)), 112.4, 117.2, 117.6, 119.1, 121.8, 126.0, 128.9, 129.3, 129.4, 132.8, 133.1, 135.3 (Ar-C), 159.4, 159.8 (C = N), and 168.4 (C-S-C).

2.4. Single-Crystal X-Ray Structure Determination. The intensity data for the single crystal of the ligand, 1, were obtained on a CrysAlisPro Oxford diffractometer fitted with graphite monochromated Cu-K\(_\alpha\) radiation (\(\lambda = 1.54 \text{\AA}\)), at 296 K, whereas the measurements for complex 3 were processed on a CCD area detector APEXII Duo diffractometer operating at 50 kV and 30 mA with Mo-K\(_\alpha\) radiation (\(\lambda = 0.71073 \text{\AA}\)) at 296 K.

SAINT and APEXII software packages were used to integrate the data, and the SADABS tool was used to perform the empirical absorption correction [20]. Direct methods using SHELXS-2014 were applied to find the solution and subsequently refined by applying the full-matrix least-squares method to F\(_2\) using SHELXL-2014 [21]. X-Seed was used as a graphic interface for SHELXL [22]. Non-hydrogen atoms were refined anisotropically, while the refinement for hydrogen atoms was isotropic. Table 1 shows the entire crystal data and refinement details.
2.5. Density Functional Theory (DFT) Calculation. Gaussian09 [23] and GaussView5 [24] software packages were used to conduct DFT calculations. The DFT approach was used to fully optimize the structure of complexes 2 and 4 utilizing the B3LYP [25, 26] hybrid exchange correlation functional with LanL2DZ pseudopotential on Cu and Zn [27–29] and the 6-311G (d, p) Pople basis set for all other atoms. The initial structures and geometries of 1 and 3 were obtained from single-crystal X-ray diffraction analysis. The DFT calculation for 1 and 3 was analysed with the same functional and basis sets. A scaling factor of 0.9682 was used to scale vibrational frequencies [30]. The HOMO-LUMO energies of the optimized geometries were calculated with time-dependent DFT (TD-DFT) measurements on the same basis set [31, 32], and the solvation effects (DMSO) were added using the polarizable continuum method (PCM) [33–35].

2.6. Hirshfeld Surface Analysis. The Hirshfeld surfaces and 2D fingerprint plots were generated using CrystalExplorer 17.5 [36]. The structural input files for 1 and 3 were obtained in the CIF format. A normalized contact, denoted by d<sub>norm</sub>, is a ratio that takes into account the distances between any surface point and the closest internal (d<sub>i</sub>) and exterior (d<sub>e</sub>) atoms, as well as the van der Waals radii of the atoms.

2.7. Cell Culture and Viability Assay. ATCC, Virginia, USA, provided human breast cancer cells with both estrogen-positive (MCF-7) and triple-negative estrogen (MDA-MB-231) receptors. Cells were grown at 37°C in RPMI-1640 (high-glucose) media with 10% fetal bovine serum comprising 1% penicillin in a moistened environment of 5% CO<sub>2</sub> in air. The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was used to assess the inhibitory effect of the ligand, 1, and its complexes 2-4 on the proliferation of breast cancer cells [12, 18, 37]. It was observed that ligand, 1, and its complexes 2-4 were nontoxic to cancer cells when they were dispersed in DMSO and diluted in culture medium to a final DMSO concentration of less than 0.05% (v/v). Cells were sown in 96-well plates at a density of 6000 cells per well for 24 hours before being exposed to various doses of chemicals for 72 hours. The wells were rinsed with 200 μL of phosphate buffer saline after the medium was removed. Each well was filled with aliquots of 20 μL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and incubated at 37°C for 4 hours. Following that, each well that had 2 μL of the medium was replaced with 200 μL of DMSO. An ELISA plate reader was used to determine optical density at 570 nm. In all of the experiments, there were control wells (100% viability) filled with medium and DMSO. The average of triplicate assays was used to generate all of the data points. GI<sub>50</sub> was used to measure cytotoxicity, which was defined as the concentration that reduced the absorbance of treated cells by 50% when compared to the control (untreated cells) [38].

2.8. DNA-Binding Studies via UV-Visible Absorption Spectroscopy. UV-Vis absorption studies were carried out to ensure the CT-DNA interaction of the ligand, 1, and complex 2 at room temperature. Throughout the absorption titrations, the concentration of the bioactive complex 2 solutions was kept constant at 50 μM, while the concentration of CT-DNA was gradually increased (4.21 × 10<sup>-5</sup> M). At room temperature, the complex was dispersed in DMSO and diluted in Tris-HCl buffer [39], with wavelength measured at 230 to 600 nm. The absorbance values were taken ten minutes after the DNA solution was injected. The following equation was used to calculate the binding constant, K<sub>b</sub>:

\[
\frac{[\text{DNA}]}{[\text{DNA}] + \frac{1}{K_b(\epsilon_b - \epsilon_f)}} = \frac{\epsilon_f - \epsilon_b}{\epsilon_b - \epsilon_f}
\]

where [DNA] denotes the base-pair concentration, \(\epsilon_b\) is the apparent molar extinction coefficient \(A_{abs}/[M]\), and \(\epsilon_f\) is the extinction coefficient for free complex 2 [M], while \(\epsilon_b\) is the extinction coefficient for the completely bound complex 2. The DNA-binding absorption studies followed the same procedure as those described in our earlier publications [19].

2.9. Molecular Docking. The Protein Data Bank [40] provided the coordinates for dodecamer d (CGGCAATTCCGG)<sub>2</sub> of B-DNA (PDB ID:1BNA). The coordinates of 2 were determined after utilizing the DFT approach to minimize energy. The AutoDock Tools version 1.5.6 and 4.2.5.1 programs were used for molecular docking investigations [41]. Water molecules were removed from the receptor and replaced with polar hydrogen atoms and Kollman charges (DNA sequences). The AutoDock parameter file was updated to include van der Waals interactions and other 2-specific parameters retrieved from the AutoDock website [42, 43]. The conformation with the lowest binding energy from the highest cluster was chosen as the best ligand-receptor binding conformation [19, 44].
3. Results and Discussion

The synthesis of dithiocarbazate Schiff base, 1, and its complexes with Cu(II), Ni(II), and Zn(II) ions is shown in Scheme 1. The isolated complexes were obtained in good yield (70–83%) and were soluble in DMSO, DMF, acetone, and chloroform at room temperature. The molar conductance values for the isolated complexes at 0.30–2.04 Ω⁻¹ cm² mol⁻¹ suggested the complexes to be non-electrolytic [45].

3.1. Spectroscopic Studies. The IR spectra for the ligand, 1, and its complexes 2-4 were determined at 400–4000 cm⁻¹ (Supplementary Information Table S1 and Figures S1–S4). The IR spectra of the ligand, 1, exhibit the characteristic bands due to v(νH) at 3086 and 3105 cm⁻¹ [46, 47]. However, the stretching bands due to v(νN) disappeared when ligand, 1, is complexed with metal ions, suggesting its deprotonation [46, 47]. Furthermore, the strong band appearing at 1600–1595 cm⁻¹ in the spectra of the ligand is assigned to v(C=O) vibration [46–52], which, however, shifted to lower wavenumber, suggesting the complexation of 1 to metal(II) ions via azomethine nitrogen atoms [46–52]. However, the same pattern was observed for the hydrazine v(N=N) band in the spectra of metal(II) complexes, suggesting the coordination of the ligand, 1, via the nitrogen lone pair, where the electron delocalization occurs through the 5-membered chelate ring [46, 47]. The disappearance of vibrations due to v(C=S) and the appearance of the splitting v(CSS) bands in the spectra of complexes provide strong evidence that the ligand has been coordinated to metal ion through the thiolate sulphur [49, 53, 54].

The ¹H NMR spectrum of 1 did not show any signal at ca. δ 4.00 ppm, attributed to S–H proton, confirming that 1 exists as thione tautomer even in solution [55]. The occurrence of a proton connected to the nitrogen atom is shown by a singlet signal at 13.29 ppm, which, however, was absent in the spectra of complexes 3 and 4, indicating the coordination of the Schiff bases to the metal ion. The ¹³C NMR spectrum of 1 showed a downfield chemical shift at δ ~ 196 ppm, indicating the existence of the C=S thione tautomer in solution. In the spectra of complexes 3 and 4, there was an upfield shift of this signal, suggesting a drop in electron density at the carbon atom as a result of the sulphur atom complexing with metal ion, confirming the structures suggested for the complexes [46–52] (Supplementary Information Figures S5–S10).

The MS spectral data revealed that the molecular ion peak identified in the spectra matches the proposed structure of the ligand, 1. The mass spectra revealed the presence of a molecular ion peak [C₁₇H₁₄N₂O₂S₂]⁺ at m/z 330, which correspond to the presence of [C₁₆H₁₆N₂O₂S₂]⁻ and [C₁₇H₁₆N₂O₂S₂]⁺ molecular ions (Supplementary Information Figure S11).

The UV-Vis spectra of 1 in DMSO at 10⁻³ M showed a high-intensity peak at 356 nm, which was assigned to n → π⁺ and π → π⁺ transitions and agrees well with the TD-DFT electron excitation at 348 nm [56]. This excitation of electrons occurs at lone pair of nitrogen atoms and aromatic phenyl ring (Figure 2). For 2–4, the HOMO is mainly located on the 3-methoxybenzyl backbone of each dithiocarbazate Schiff bases and the metal centre, whereas the LUMO mainly resides on 3-methoxybenzyl and backbone of dithiocarbazate Schiff bases. Table S2 contains the UV/Vis data for all compounds.

3.2. X-Ray Structure Crystallography. Single-crystal X-ray diffraction data revealed the structures of the ligand, 1, and its complex 3. The selected bond lengths and bond angles of 1 and 3 are presented in Table 2. 1 crystallizes in monoclinic space group P2₁/n with the whole molecule arranged in an asymmetric unit. In 1, the dithiocarbazate backbone (C₂→S₂→C₁→S₁→N₂) and (N₁→C₁₀→C₁₁→C₁₂→C₁₃→C₁₄→C₁₅→C₁₆→O₁→C₁₇) moiety could be considered that almost coplanar conformation with dihedral angle is shown at 7.19 (5)°. The bond lengths of S₂→C₁ = 1.7564 (17) Å, S₁→C₁ = 1.6743 (18) Å, N₂→C₁ = 1.335 (2) Å, and N₁→S₁ = 1.376 (2) Å are fall in expected value and almost similar to the those reported literature [53, 57]. The ligand, 1, behaves similarly to a thione tautomer in the solid state as it is observed in solution. Intramolecular hydrogen bond interactions are observed in the ligand with the imine group being the hydrogen bond donor to the adjacent sulphur atom of the next nearest molecule. The separation for this interaction, N₂–H₂···S₁, is determined to be 2.571 (6) Å (Figure 3).

3 crystallizes in triclinic space group P-1 with half of the molecule forming an asymmetric unit (Figure 4). The coordination sphere of the central Ni1 ion is occupied by two imine nitrogen and two sulphur atoms of two ligands, which are arranged in anti-conformation. The central Ni ion displays a square planar geometry with the geometry index, τ = 0. The distances of Ni1-N1 and Ni1–S1 are 1.889 (6) Å and 2.153 (8) Å, respectively, are comparable to the similar constituted complexes such as [Ni(L₁) (py)] [Ni-N₂ = 1.884 (7) Å, N₁-S₁ = 2.170 (3) Å] [58] and NiL₂[N₁–Ni₁ = 1.9010 (2) Å, Ni₁-S₁ = 2.2015 (9) Å] [57]. These bond lengths are marginally shorter than the equivalent bonds in the oxomolybdenum(VI) [59], tin(IV) [60], and copper(II) [61] complexes of related dithiocarbazate ligands. In the crystal packing of 3, the π–π interactions are the most dominant in stabilizing the structure with the closest separation being 3.823 (5) Å due to the lack of any potential hydrogen bond donor (Figure 5(a)). Further observation on the supramolecular π–π interactions within complex 3 has revealed that the aromatic moieties in complex 3 are arranged interdigitating to each other (Figure 5(b)).

3.3. Hirshfeld Surface Analysis. The intermolecular interaction of crystal structures of 1 and 3 was quantified through the Hirshfeld surface analysis and 2D fingerprint plots using CrystalExplorer 17.5 [36]. The Hirshfeld surface mapped over dnorm 1 and 3 is shown in Figures 6(a) and 6(b), respectively. There are bright-red spot regions in 1, demonstrating the occurrence of a strong hydrogen bond connecting the neighbouring molecules via N₂–H₂···S₁.
However, no strong hydrogen bond interaction is visualized in 3. From the 2D fingerprint plots (Figure S12), the greatest percentage contributions to the Hirshfeld surface for 1 (48.4%) and 3 (44.8%) are shown by the sharp spike characteristic at $d_e + d_i \sim 2.2 \text{ Å}$ representing H···H contact. The H···C/C···H contact is the second most important contributor to intermolecular interactions, accounting for 23.6% for 1 and 26.4% for 3, and is shown by a pair of peak characteristic at $d_e + d_i \sim 3.2 \text{ Å}$. These contacts may be due to the occurrence of C–H···π interactions in the compounds (Table 3). On the Hirshfeld surface mapped with the shape index, the corresponding C–H···π interactions (marked with circles in Figure S13) are observed for compounds 1 and 3. The presence of intermolecular N–H···S interactions in 1 is corroborated by a pair of sharp peaks at $d_e + d_i \sim 3.0 \text{ Å}$, which constitute 15.9% of the H···S/S···H contact. The proportions of H···N/N···H, H···O/O···H, C···S/S···C, C···N/N···C, C···C, S···N/N···S, C···O/O···C, and S···O/O···S interactions showed that an inferior contribution for 1 comprised 3.0%, 2.6%, 2.2%, 1.7%, 1.1%, 0.4%, 0.2%, and 0.1% of the Hirshfeld surface, respectively. In 3, the weak contacts are attributed to H···N/N···H, H···O/O···H, H···Ni/Ni···H, C···S/

**Table 2: Selected bond lengths and bond angles of 1 and 3.**

| Bond lengths (Å)          | Bond angles (°) |
|--------------------------|-----------------|
| S2→C2                   | 1.8199 (18)     | C1→S2→C2       | 101.93 (9) |
| S2→C1                   | 1.7564 (17)     | N2→C1→S1       | 122.03 (13) |
| S1→C1                   | 1.6743 (18)     | S1→C1→S2       | 124.82 (11) |
| N2→C1                   | 1.335 (2)       | C1→N2→H2       | 120.8 (14) |
| N1→C10                  | 1.281 (2)       | C1→N2→N1       | 119.05 (14) |
| N2→N1                   | 1.376 (2)       | C10→N1→N2      | 116.63 (14) |
| C3→C2                   | 1.514 (2)       |                  |             |
| Ni1→N1                  | 1.889 (5)       | N1→Ni1→N1      | 180.0       |
| Ni1→S1                  | 2.153 (2)       | N1→Ni1→S1      | 85.75 (19)  |
| Ni1→S1                  | 2.153 (2)       | N1→Ni1→S1      | 94.25 (19)  |
| C1→N2                   | 1.277 (7)       | S1→Ni1→S1      | 180.0       |
| C1→S1                   | 1.698 (7)       |                  |             |
| C1→S21.727 (7)          |                  |                  |             |

Figure 2: Frontier MOs of the Schiff base 1 and its complexes (2–4).
Table 3: Hydrogen bond geometry and intermolecular interactions (Å, °).

| D→H-A   | D→H     | H···A    | D→A     | D→H···A |
|---------|---------|----------|---------|---------|
| 1       | N2→H2···S1 | 0.85 (2) | 2.57 (2) | 3.4128 (17) | 169.3 (18) |
| X→H−Cg | X→H     | H−Cg     | X−Cg    | X→H−Cg  |

Intermolecular hydrogen bond

| D→H-A   | D→H     | H···A    | D→A     | D→H···A |
|---------|---------|----------|---------|---------|
| 1       | C14→H14−Cg1 | 2.75     | 3.518 (2) | 141 |
| C17→H17C−Cg1 | 2.91 | 3.415 (2) | 114 | 3/2−X, 1/2+Y, 3/2−Z |

X→H···π interactions

| D→H-A   | D→H     | H···A    | D→A     | D→H···A |
|---------|---------|----------|---------|---------|
| 1       | C14→H4−Cg1 | 2.73     | 3.537 (8) | 143 |
| C17→H4−Cg2 | 2.73 | 3.537 (8) | 143 | −1+X, Y, Z |
| C7→H7−Cg1 | 2.89 | 3.833 (9) | 172 | 1−X, −Y, 3−Z |
| C17→H17C−Cg3 | 2.81 | 3.639 (9) | 142 | 1+X, 1+Y, Z |

Figure 3: Structure of 1. Symmetry elements used: (a) \( i = -x, 2-y, -z \), and (b) \( i = -x, 1-y, 2-z \).

Figure 4: Structure of 3 with ellipsoids shown at 50% probability. Selected bond lengths [Å] and angles [°]: Ni1−N1 = 1.889 (6); Ni1−S1 = 2.153 (8); Ni−N2 = 1.393 (8); N1−Ni1−Ni1 = 180; and S1−Ni1−S1i = 180. Symmetry element used: \( i = -x, -y, 2-z \).
involved 3.7%, 3.2%, 2.3%, 1.8%, 1.3%, 1.3%, 0.4%, and 0.1%, respectively. Overall, these intermolecular interactions provide further stability in the crystal structure of both compounds [36].

3.4. Cytotoxic Activity. The cytotoxicity of studied compounds was tested against two breast cancer cell lines: MCF-7 and MDA-MB-231. With the exception of 2, none of the other compounds tested inhibited both cell lines significantly. The GI50 value of 0.85 μM and 0.37 μM suggests that 2...
is considered as strongly active against MDA-MB-231 and MCF-7 cancer cells, respectively as compared to cisplatin (GI\textsubscript{50} \(\leq 12.0\) μM (MDA-MB-231) and 6.5 μM (MCF-7)) [56]. Based on the data obtained, 2 is more sensitive to estrogen receptor-positive breast cancer (MCF-7) cells. This is where estrogen hormones play an essential role in treating cancers compared with triple-negative estrogen receptors (MDA-MB-231). Besides, 2 could induce chromatin condensation and nuclear fragmentation, suggesting the presence of apoptotic bodies of cells [7]. However, the complexation of the 1 with Cu(II) ions brings a significant decrease in the polarity of copper ions. Therefore, the resulting increase in the lipophilic property of the Cu(II) ion brings an increase in the permeability of the Cu(II) complex across the lipid bilayer of the cell membrane [48]. In addition, the hydration energy release in aquatic media favours the reduction of Cu(II) to Cu(I), whereas Zn(II) and Ni(II) do not undergo this reduction [62]. As a result, complex 2 investigated in this experiment could be a promising anticancer therapeutic candidate that warrants further exploration into its mechanism of action.

### 3.5. DNA-Binding Studies

#### 3.5.1. Absorption Spectroscopic Studies

UV-Vis absorption spectral titrations were performed to explore the interactions between cytotoxic complex 2 and CT-DNA. Figure 7 shows the absorption spectra of 2 in the absence and presence of CT-DNA as a function of concentration. Complex 2 exhibited a strong absorption peak at \(\lambda_{\text{max}}\) 342, corresponding to \(\pi \rightarrow \pi^*\) intra-ligand transition of the aromatic chromophore. The intensity of the prominent absorption was reduced as the concentration of CT-DNA was increased, and a bathochromic shift (1 to 5 nm) was observed in 2. The changes reveal that the aromatic chromophore of 2 exhibits promising interactions with the aromatic base pairs of the DNA, suggesting a good binding with a 25.51% hypochromic shift. The intrinsic binding constant \((K_b)\) of 2 was \(2.55 \times 10^4\) M\(^{-1}\), which is consistent with previous reports showing intermediate binding interactions between complexes and CT-DNA [63]. The obtained values were lower than those of the classical intercalator (ethidium-DNA, \(3 \times 10^6\) M\(^{-1}\)) [64]. This indicates that 2 has a less binding affinity to the CT-DNA than ethidium bromide [63–65].

#### 3.5.2. Molecular Docking Simulation

Molecular docking simulation plays a significant role in the development of new chemotherapeutic drugs. It is used to understand the interactions between synthesized drugs and DNA, supporting the experimental investigation of DNA binding. The conformation of docked complex 2 was analysed based on binding energy and non-covalent (hydrogen bonding, major or minor groove, and electrostatic) interactions between complex 2 and DNA. The labelled DNA duplex of sequenced \((\text{CGCGAATTCGCG})_2\) dodecamer used is given in Figure 8(a). The molecular docking of 2 with DNA duplex yielded the most suitable docked poses (Figure 8(b)). As illustrated in Figure 8(c), we can express that the 2 fit closely into the G-C region of DNA via hydrogen bonding and hydrophobic and van der Waals interactions with binding energy \(-7.39\) kcal/mol. This demonstrates the higher binding affinity in the G-C region compared with the adenine-thymine (AT)-rich region with a binding energy of \(-4.38\) kcal/mol. The G-C region is crucial in DNA stability
because three hydrogen bonds stabilize guanine and cytosine, and it has been suggested that targeting these regions could have a key role in anticancer activity [66, 67]. Complex 2 forms two carbon-hydrogen bonds between the C atom of complex 2 with phosphate groups of adenine-18 and cytosine-11 with the bond distance of 3.32 and 3.44 Å, respectively. The other non-covalent bonds between 2 and DNA bases are shown in Figure 8(c). Significant cytotoxicity was observed, although DNA-binding studies revealed that complex 2 did not strongly bind to DNA. The mechanism of action of complex 2 remains unknown and is a subject for future research.

Figure 8: (a) DNA duplex of sequence (PDB ID: 1BNA) with labels. (b) The lowest binding energy conformation between 2 with DNA. (c) Molecular docked model showing the interactions of 2 with DNA.
4. Conclusions

A number of physicochemical studies and single-crystal X-ray diffraction analysis were performed to investigate the diethiocarbazate Schiff base ligand 1 and its complexes 2, 3, and 4. The in vitro cytotoxic activity of the synthesized compounds against MCF-7 and MDA-MB-231 cells was tested. However, only complex 2 demonstrated significant cytotoxic potency against both cancer cells. The absorbance and molecular docking simulations were used to further investigate the DNA-binding studies of 2, which reveal that 2 binds to DNA rather effectively via hydrogen bonding and hydrophobic, and van der Waals interactions. The obtained data correlate well with the cytotoxicity of the complex, indicating that 2 has the potential to be a promising anticancer candidate.

Data Availability

CCDC 2106915 (1) and 2106916 (3) contain all crystallographic data and can be obtained free of charge via the Cambridge Crystallographic Data Centre.

Conflicts of Interest

The authors do not have any conflicts of interest.

Acknowledgments

This research was funded by Universiti Sains Malaysia under the Short-Term Grant Scheme (304/PJAUH/6315525). The authors acknowledge the financial support through Researchers Supporting Project Number (RSP-2021/147), King Saud University, Riyadh, Saudi Arabia. The authors thank the School of Distance Education and School of Chemical Sciences, Universiti Sains Malaysia, Department of Chemistry, Faculty of Science and the Molecular Genetics Laboratory, Faculty of Medicine and Health Sciences, and Universiti Putra Malaysia for their facilities.

Supplementary Materials

Table S1. Experimental and calculated FTIR vibrations (cm⁻¹) for the Schiff bases 1 and its Cu(II), Ni(II), and Zn(II) complexes (2–4). Table S2. Experimental and calculated electronic spectral data of the Schiff bases 1 and its Cu(II), Ni(II), and Zn(II) complexes (2–4). Figure S1. FTIR spectrum of 1. Figure S2. FTIR spectrum of 2. Figure S3. FTIR spectrum of 3. Figure S4. FTIR spectrum of 4. Figure S5. ¹H NMR spectrum of 1. Figure S6. ¹³C NMR spectrum of 1. Figure S7. ¹H NMR spectrum of 3. Figure S8. ¹³C NMR spectrum of 3. Figure S9. ¹H NMR spectrum of 4. Figure S10. ¹³C NMR spectrum of 4. Figure S11. Mass spectrum of Schiff base 1. Figure S12. Fingerprint plots of all H····H, H····C/C····H, and H····S/S····H interactions, showing the percentage of contacts contribute to the total Hirshfeld surface area of (a) 1 and (b) 3. Figure S13. Hirshfeld surface of compounds (a) 1 and (b) 3 plotted over shape index. (Supplementary Materials)

References

[1] N. Farrell, *Transition Metal Complexes as Drugs and Chemotherapeutic Agents*, Kluwer Academic Publishers, The Netherlands, 1989.
[2] H. L. Singh and A. K. Varshney, “Synthesis and characterization of coordination compounds of organotin(IV) with nitrogen and sulfur donor ligands,” *Applied Organometallic Chemistry*, vol. 15, pp. 762–768, 2001.
[3] M. Nath, R. Yadav, G. Eng, T. T. Nguyen, and A. Kumar, “Characteristic spectral studies, and antibacterial and anti-inflammatory activities of diorganotin(IV) derivatives of dipeptides,” *Journal of Organometallic Chemistry*, vol. 577, pp. 1–8, 1999.
[4] P. Subbaraj, A. Ramu, N. Raman, and J. Dharmaraja, “Synthesis, characterization, DNA interaction and pharmacological studies of substituted benzophenone derived Schiff base metal(II) complexes,” *Journal of Saudi Chemical Society*, vol. 19, no. 2, pp. 207–216, 2015.
[5] M. Azam, I. Warad, S. Al-Resayas et al., “A novel Ru(II) complex derived from hydroxydiamine as a potential antitumor agent: synthesis and Structural Characterization,” *Inorganic Chemistry Communications*, vol. 20, pp. 252–258, 2012.
[6] F. Tsaito, C. Marzano, M. Porchia, M. Pelleli, and C. Santini, “Copper in diseases and treatments, and copper-based anticancer strategies,” *Medicinal Research Reviews*, vol. 30, no. 4, pp. 708–749, 2010.
[7] C. Marzano, M. Pelleli, F. Tsaito, and C. Santini, “Copper complexes as anticancer agents,” *Anti-Cancer Agents in Medicinal Chemistry*, vol. 9, no. 2, pp. 185–211, 2009.
[8] C. Santini, M. Pelleli, V. Gandin, M. Porchia, F. Tsaito, and C. Marzano, “Advances in copper complexes as anticancer agents,” *Chemical Reviews*, vol. 114, no. 1, pp. 815–862, 2014.
[9] S. Sukkur Saleem, M. Sankarganesh, P. Advin Jose, and J. Dhaveethu Raja, “Design, synthesis, antioxidant, antimicrobial, DNA binding and molecular docking studies of morpholine based Schiff base ligand and its metal(II) complexes,” *Inorganic Chemistry Communications*, vol. 124, Article ID 108396, 2021.
[10] H. Kargar, R. Behjatmanesh-Ardakani, V. Torabi et al., “Novel copper(II) and zinc(II) complexes of halogenated bidentate N, O-donor Schiff base ligands: synthesis, characterization, crystal structures, DNA binding, molecular docking, DFT and TD-DFT computational studies,” *Inorganica Chimica Acta*, vol. 514, Article ID 120004, 2021.
[11] M. Shakir, N. Shahid, N. Sani, M. Azam, and A. U. Khan, “Synthesis, spectroscopic characterization and comparative DNA binding studies of Schiff base complexes derived from 1-leucine and glyoxal,” *Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy*, vol. 82, no. 1, pp. 31–36, 2011.
[12] E. N. M. Yusof, T. B. S. A. Ravoof, J. Jamsari et al., “Synthesis, characterization and biological studies of S-4-methylbenzyl-β-N-(2-furylmethylene) dithiocarbazate (S4MFuH) its Zn²⁺, Cu²⁺, Cd²⁺ and Ni²⁺ complexes,” *Inorganica Chimica Acta*, vol. 438, pp. 85–93, 2015.
[13] F. Ramilo-Gomes, Y. Addis, I. Tekamo et al., “Antimicrobial and antitumour activity of S-methyl dithiocarbazate Schiff base zinc(II) complexes,” *Journal of Inorganic Biochemistry*, vol. 216, Article ID 111331, 2021.
Schiff bases derived from S-methylthiocarbazate (SMDTC) and the X-ray structure of the bis [S-methyl-β-N-(2-furylmethylene) dihydrocarbazato]cadmium(II) complex,” Polyhedron, vol. 23, no. 8, pp. 1385–1392, 2004.

[15] M. L. Low, L. Maigre, M. I. M. Tahir et al., “New insight into the structural, electrochemical and biological aspects of macrocyclic Cu(II) complexes derived from S-substituted dihydrocarbazate Schiff bases,” European Journal of Medicinal Chemistry, vol. 120, pp. 1–12, 2016.

[16] F. N.-F. How, K. A. Crouse, M. I. M. Tahir, M. T. H. Tafadar, and A. R. Cowley, “Synthesis, characterization and biological studies of S-benzyl-β-N-(benzoyl) dihydrocarbazate and its metal complexes,” Polyhedron, vol. 27, no. 15, pp. 3325–3329, 2008.

[17] E. Zangrando, M. S. Begum, M. C. Sheikh et al., “Synthesis, characterization, density functional study and antimicrobial evaluation of a series of bischelated complexes with a dihydrocarbazate Schiff base ligand,” Arabian Journal of Chemistry, vol. 10, no. 2, pp. 172–184, 2017.

[18] E. Md Yusof, T. B. S. A. Ravoof, E. R. T. Tiekink et al., “α-Vanillin derived Schiff bases and their organotin(IV) compounds: synthesis, structural characterisation, in-silico studies and cytotoxicity,” International Journal of Molecular Sciences, vol. 16, no. 12, pp. 11034–11054, 2015.

[19] E. N. M. Yusof, M. A. M. Latif, M. I. M. Tahir et al., “New insight into the structural, electrochemical and biological aspects of 2-methylbenzyl 2-(dipyridin-2-ylmethylene) hydrazinecarbodithioate,” International Journal of Molecular Sciences, vol. 17, 2016.

[20] R. H. Blessing, “An empirical correction for absorption anisotropy,” Acta Crystallographica Section A Foundations of Crystallography, vol. 51, no. 1, pp. 33–38, 1995.

[21] G. M. Sheldrick, “Crystal structure refinement with SHELXL,” Acta Crystallographica Section C: Structural Chemistry, vol. 71, no. 1, pp. 3–8, 2015.

[22] L. J. Barbours, “X-seed - a software tool for supramolecular crystallography,” Journal of Supramolecular Chemistry, vol. 1, no. 4-6, pp. 189–191, 2001.

[23] M. J. Frisch, G. W. Trucks, H. B. Schlegel et al., Gaussian 09, Revision D.01, Gaussian, Inc, Wallingford UK, 2013.

[24] D. Roy, K. Todd, and M. John, “GaussView Ver 5.0.9,” 2009.

[25] C. Lee, W. Yang, and R. G. Parr, “Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density,” Physical Review B, vol. 37, no. 2, pp. 785–789, 1988.

[26] A. D. Becke, “Density-functional thermochemistry. III. The role of exact exchange,” The Journal of Chemical Physics, vol. 98, no. 7, pp. 5648–5652, 1993.

[27] P. J. Hay and W. R. Wadt, “Ab initio effective core potentials for molecular calculations. Potentials for the transition metal atoms Sc to Hg,” The Journal of Chemical Physics, vol. 82, no. 1, pp. 270–283, 1985.

[28] P. J. Hay and W. R. Wadt, “Ab initio effective core potentials for molecular calculations. Potentials for K to Au including the outermost core orbitals,” The Journal of Chemical Physics, vol. 82, no. 1, pp. 299–310, 1985.

[29] W. R. Wadt and P. J. Hay, “Ab initio effective core potentials for molecular calculations. Potentials for main group elements Na to Bi,” The Journal of Chemical Physics, vol. 82, no. 1, pp. 284–298, 1985.

[30] J. P. Merrick, D. Moran, and L. Radom, “An evaluation of harmonic vibrational frequency scale factors,” The Journal of Physical Chemistry A, vol. 111, no. 45, pp. 11683–11700, 2007.

[31] K.-Y. Chen and H.-Y. Tsai, “Synthesis, X-ray structure, spectroscopic properties and DFT studies of a novel Schiff base,” International Journal of Molecular Sciences, vol. 15, no. 10, pp. 18706–18724, 2014.

[32] G. Scalfani, M. J. Frisch, B. Mennucci, J. Tomasi, R. Cammi, and V. Barone, “Geometries and properties of excited states in the gas phase and in solution: theory and application of a time-dependent density functional theory polarizable continuum model,” The Journal of Chemical Physics, vol. 124, no. 9, Article ID 094107, 2006.

[33] E. Cancès, B. Mennucci, and J. Tomasi, “A new integral equation formalism for the polarizable continuum model: theoretical background and applications to isotropic and anisotropic dielectrics,” The Journal of Chemical Physics, vol. 107, no. 8, pp. 3032–3041, 1997.

[34] J. Tomasi and M. Persico, “Molecular interactions in solution: an overview of methods based on continuous distributions of the solvent,” Chemical Reviews, vol. 94, no. 7, pp. 2027–2094, 1994.

[35] J. Tomasi, B. Mennucci, and R. Cammi, “Quantum mechanical continuum solvent models,” Chemistry Review, vol. 105, no. 8, pp. 2999–3094, 2005.

[36] M. J. Turner, J. J. McKinnon, S. K. Wolff et al., Crystal Explorer, vol. 17, 2017.

[37] S. A. Omar, T. B. S. A. Ravoof, M. I. M. Tahir, and K. A. Crouse, “Synthesis and characterization of mixed-ligand copper(II) saccharinate complexes containing tridentate NNS Schiff bases. X-ray crystallographic analysis of the free ligands and one complex,” Transition Metal Chemistry, vol. 39, no. 1, pp. 119–126, 2013.

[38] T. Mosmann, “Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays,” Journal of Immunological Methods, vol. 65, no. 1-2, pp. 55–63, 1983.

[39] K. Liu, H. Yan, G. Chang, Z. Li, M. Niu, and M. Hong, “Organotin(IV) complexes derived from hydrazone Schiff base: synthesis, crystal structure, in vitro cytotoxicity and DNA/BSA interactions,” Inorganica Chimica Acta, vol. 464, pp. 137–146, 2017.

[40] Protein Data Bank, “RCSB,” 2021, https://www.rcsb.org/.

[41] G. M. Morris, R. Huey, W. Lindstrom et al., “AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility,” Journal of Computational Chemistry, vol. 30, pp. 2785–2791, 2009.

[42] B. J. Bender, S. Gabbauer, A. Lutters et al., “A practical guide to large-scale docking,” Nature Protocols, vol. 16, no. 10, pp. 4799–4832, 2021.

[43] ADL, “Parameters for docking with metal ions in receptor,” 2009, http://autodock.1369657.n2.nabble.com/ADL-Parameters-for-docking-with-metal-ions-in-receptor-td2505649.html.

[44] W. Rehm, R. Yasmine, F. Rahim et al., “Synthesis biological screening and molecular docking studies of some tin(IV) Schiff base adducts,” Journal of Photochemistry and Photobiology B: Biology, vol. 164, pp. 65–72, 2016.

[45] W. J. Geary, “The use of conductivity measurements in order for the characterisation of coordination compounds,” Coordination Chemistry Reviews, vol. 7, no. 1, pp. 81–122, 1971.

[46] T. B. S. A. Ravoof, K. A. Crouse, M. I. M. Tahir, R. Rosli, D. J. Watkin, and F. N. F. How, “Synthesis, characterisation and biological activities of 2-methylbenzyl 2-(dipyridin-2-ylmethylene) hydrazinecarbodithioate,” Journal of Chemical Crystallography, vol. 41, no. 4, pp. 491–495, 2011.
[47] M. H. A. Hamid, A. N. A. H. Said, A. H. Mirza et al., “Synthesis, structures and spectroscopic properties of some tin(IV) complexes of the 2-acetylpyrazine Schiff bases of S-methyl- and S-benzylthiocarbazates,” *Inorganica Chimica Acta*, vol. 453, pp. 742–750, 2016.

[48] A. M. Ali, S. u. H. Majumder, R. J. Butcher, J. P. Jasinski, and J. M. Jasinski, “The preparation and characterization of bis-chelated nickel(II) complexes of the 6-methylpyridine-2-carboxaldehyde Schiff bases of S-alkyldithiocarbazates and the X-ray crystal structure of the bis-[S-methyl-β-N-(6-methylpyrid-2-yl)-methylenedithiocarbazato] nickel(II) complex,” *Polyhedron*, vol. 16, pp. 2749–2754, 1997.

[49] M. A. Salam, M. Alam, S. Sarker, and M. M. Rahman, “Synthesis, spectroscopic characterization, crystal structure, and anti-bacterial activity of diorganotin(IV) complexes with 5-bromo-2-hydroxybenzaldehyde-N-(4-ethyl-thiosemicarbazone),” *Journal of Coordination Chemistry*, vol. 71, no. 10, pp. 1593–1605, 2018.

[50] T.-J. Khoo, M. K. B. Break, K. A. Crouse et al., “Synthesis, characterization and biological activity of two Schiff base ligands and their nickel(II), copper(II), zinc(II) and cadmium(II) complexes derived from diorganotin(IV) complexes and X-ray crystal structure of cadmium(II) complex derived from pyridine-2-carboxaldehyde,” *Inorganica Chimica Acta*, vol. 413, pp. 68–76, 2014.

[51] N. N. M. Ishak, J. Jamsari, A. Z. Ismail et al., “Synthesis, characterization and biological studies of mixed-ligand nickel(II) complexes containing imidazole derivatives and thiosemicarbazide Schiff bases,” *Journal of Molecular Structure*, vol. 1198, Article ID 126888, 2019.

[52] J. O. Adeyemi and D. C. Onwudie, “Organotin(IV) di-thiocarbamate complexes: chemistry and biological activity,” *Molecules*, vol. 23, no. 10, p. 2571, 2018.

[53] R. A. Haque and M. A. Salam, “Synthesis, structural, and spectral studies of diorganotin(IV) complexes with 2-hydroxy-5-methylbenzaldehyde-N-(4-cyclohexylthiosemicarbazone),” *Journal of Coordination Chemistry*, vol. 69, no. 4, pp. 714–725, 2016.

[54] A. Shanmugapriya, R. Jain, D. Sabarinathan, G. Kaliarasi, F. Dallemer, and R. Prabhakaran, “Structurally different mono-bi- and trinuclear Pd(II) complexes and their DNA/protein interaction, DNA cleavage, and anti-oxidant, anti-microbial and cytotoxic studies,” *New Journal of Chemistry*, vol. 41, no. 18, pp. 10324–10338, 2017.

[55] K. A. Crouse, K. B. Chew, M. T. H. Targarfar et al., “Synthesis, characterization and bio-activity of S-2-picolylthiocarbazate (2P2CTC), some of its Schiff bases and their Ni(II) complexes and X-ray structure of S-2-picolyl-β-N-(2-acetylpyrrole) dithiocarbamate,” *Polyhedron*, vol. 23, no. 1, pp. 161–168, 2004.

[56] Q. T. Nguyen, P. N. Pham Thi, and V. T. Nguyen, “Synthesis, characterization, and in vitro cytotoxicity of unsymmetrical tetradeinate Schiff base Cu(II) and Fe(III) complexes,” *Bioinorganic Chemistry and Applications*, vol. 2021, Article ID 6696344, 1–10 pages, 2021.

[57] Y. Liu, H. Wang, J. Zhang et al., “Synthesis, crystal structures and third-order nonlinear optical properties in the near-IR range of two novel Ni(II) complexes,” *Optical Materials*, vol. 36, no. 3, pp. 687–696, 2014.

[58] H. Khaledi, H. Mohd Ali, and M. M. Olmstead, “Coordination behavior of three geometric isomers of indole-based S-benzylthiocarbazone ligands towards nickel, zinc and cadmium divalent ions,” *Inorganica Chimica Acta*, vol. 366, no. 1, pp. 233–240, 2011.

[59] N. R. Pramanik, S. Ghosh, T. K. Raychaudhuri, S. Ray, R. J. Butcher, and S. S. Mandal, “Synthesis, characterization and crystal structure of oxomolybdenum(VI) and(IV) complexes of some tridentate ONS donor ligands,” *Polyhedron*, vol. 23, no. 9, pp. 1595–1603, 2004.

[60] E. N. Md Yusof, M. A. M. Latif, M. I. M. Tahir et al., “Homoleptic tin(IV) compounds containing tridentate ONS dithiocarbazate Schiff bases: synthesis, X-ray crystallography, DFT and cytotoxicity studies,” *Journal of Molecular Structure*, vol. 1205, Article ID 127635, 2020.

[61] M. A. Islam, M. C. Sheikh, M. A. Mumit, R. Miyatake, M. A. Alam, and M. O. A. Mondal, “Synthesis, characterization and antimicrobial activity of a bidentate NS Schiff base of S-benzyl dithiocarbazate and its diveral complexes,” *Journal of Coordination Chemistry*, vol. 69, no. 23, pp. 3580–3592, 2016.

[62] M. A. Islam, M. C. Sheikh, M. A. Mumit, R. Miyatake, M. A. Alam, and M. O. A. Mondal, “Synthesis, characterization and antimicrobial activity of a bidentate NS Schiff base of S-benzyl dithiocarbazate and its diveral complexes,” *Journal of Coordination Chemistry*, vol. 69, no. 23, pp. 3580–3592, 2016.

[63] N. Graf and S. J. Lippard, “Redox activation of metal-based prodrugs as a strategy for drug delivery,” *Advanced Drug Delivery Reviews*, vol. 64, no. 11, pp. 993–1004, 2012.

[64] A. F. Shoair, A. A. El-bindary, N. A. El-ghamaz, and G. N. Rezk, “Synthesis, characterization, DNA binding and antitumor activities of Cu(II) complexes,” *Journal of Molecular Liquids*, vol. 269, pp. 619–638, 2018.

[65] C. Miskolci, I. Labádi, T. Kurihara, N. Motohashi, and J. Molnár, “Guanine–cytosine rich regions of plasmid DNA can be the target in anti-plasmid effect of phenothiazines,” *International Journal of Antimicrobial Agents*, vol. 14, no. 3, pp. 243–247, 2000.

[66] C. Vidya Rani, M. P. Kesavan, S. Haseena, R. Varatharaj, J. Rajesh, and G. Rajagopal, “Bidentate Schiff base ligands appended metal(II) complexes as probes of DNA and Plasma protein: in silico molecular modelling studies,” *Applied Biochemistry and Biotechnology*, vol. 191, no. 4, pp. 1515–1532, 2020.